closely correlated with the onset of leukemia. Advances in molecular genetics have demonstrated that many fusion genes are difficult to detect with conventional karyotyping and highlight the value of molecular genetics in the diagnosis and treatment of leukemia.
The TEL gene, also known as the ETV6 gene, was first identified in chronic myelomonocytic leukemia as part of a fusion with the PDGFRβ receptor gene [8] . Subsequently, many cases of ALL with TEL gene rearrangement have been reported and a partner gene was found to be the AML gene located on chromosome 21 [9] . Such a fusion gene has been found in approximately 20-25% of ALL cases in children, but less than 0.05% of these can be detected with conventional cytogenetic studies. Most patients are between the ages of 1 and 10 years, white cell count < 50,000/μL, with a B immunophenotype [9] [10] [11] .
Studies by the Dana Farber Cancer Institute and St Jude's Children Hospital demonstrated that patients with the TEL/AML1 fusion gene had an excellent prognosis (100% 8-year event-free survival and 92% 5-year event-free survival, respectively) [12, 13] . However, the British-Frankfurt-Muenster leukemia group later identified the TEL/AML1 fusion gene in 25% of ALL patients who relapsed [14] [15] [16] , and that better prognostic outcome was probably associated with stronger chemotherapy regimens in the past [17] . Thus, the correlation between the TEL/AML1 fusion gene and disease prognosis requires further investigation.
This study recruited both newly diagnosed and relapsed ALL children. By employing reverse transcriptase-polymerase chain reaction (RT-PCR), the translocation t(12;21) producing the TEL/AML1 fusion gene was detected. Their correlations with the local incidence of disease and other prognostic factors (including age, white cell count, and immunophenotype of disease) were explored and analyzed. Furthermore, the TEL/AML1 fusion gene was used as a marker of the relative changes in residual illness during the course of therapy.
MATERIALS AND METHODS

Patients and samples
We recruited 25 ALL patients diagnosed between January 2003 and October 2004. Of these, 20 were newly diagnosed and five were in relapse. Following diagnosis, patients began the treatment protocol recommended by the Taiwan Pediatric Oncology Group (TPOG). Information about the subjects, including age, gender, WBC count, and central nervous system (CNS) status, is summarized in Table 1 .
After the diagnosis or onset of relapse of ALL and prior to the initiation of treatment, bone marrow and peripheral blood samples were collected. Bone marrow or peripheral blood samples were also collected from 15 subjects 14 days after induction therapy, at the completion of induction or commencement of consolidation therapy, and at commencement of maintenance therapy. A total of 46 bone marrow samples and 37 peripheral blood samples were obtained.
RT-PCR
RNA was extracted from bone marrow and peripheral blood samples and cDNA was synthesized. The target genes were amplified using the cDNA as a template and the synthetic, two-fragment specific primers. The PCR primer sequences were based on those used by van Dongen and colleagues [10] , as detailed below: TEL-A, 5Ј-CCCTCTGATCCTGAAC-3Ј (anti-sense), AML1-B, 5Ј-AACGCCTCGCTCATCTTGC-3Ј (sense), TEL-C, 5Ј-AAGCCCATCAACCTCTCTCATC-3Ј (antisense), and AML1-D, 5Ј-TGGAAGGCGGCGTGAA-GC-3Ј (sense). Primers A and B were used in the first round of a nested PCR; then, primers C and D were used in the second round. Electrophoresis was used to determine the sizes of the final products. The PCR products from the first and second rounds of PCR were 181 and 142 bps, respectively, and the REH-cell line was used as a positive control.
The cDNA prepared from reverse transcription was blotted on a nylon membrane, allowed to dry, and secured with XL-1000 CrossLinker (Spectronics, Westbury, NY, USA). A probe was prepared by PCR amplification of the REH cell cDNA with the primers TEL-C and AML1-D. The PCR products were subsequently verified by electrophoretic analysis, purified, and labeled with DIG by DIG High Prime (Roche Applied Science, Indianapolis, IN, USA) at 37°C for 2 hours. The membrane was then hybridized with DIGlabeled probes for 12-16 hours at 42°C. Following posthybridization washing and blocking, the anti-DIG AP conjugate was added, and the mixture was washed again. NBT/BCIP solution was then added for staining. The β-actin housekeeping gene was amplified with the primers 5Ј-GACATCCGCAAAGACCTGTA-3Ј and 5Ј-CAGGAGGAGCAATGATCTTG-3Ј.
TEL/AML1 and β-actin blotting analyses were carried out for each sample for comparison of the chromogenic reactions between the two variables. The results are presented as the ratio of TEL/AML1 to β-actin.
RESULTS
The results of the bone marrow and peripheral blood examinations of all 25 study subjects prior to the start of chemotherapy are summarized in Table 2 . Eight (32%) of them had detectable TEL-AML1 fusion transcripts, including six (30%) of the 20 newly diagnosed cases and two (40%) of the five relapsed cases. Table 3 shows the immunophenotypes of the ALL patients in this study. The pre-B type was the most common in the newly diagnosed patients (six patients), followed by precursor B (five cases), and early pre-B (four cases) types. The other cases included one with progenitor B, two with early pre-B with myeloid coexpression, and two with T cell immunophenotypes. Of the relapsed cases, two were precursor B type, two had early pre-B type, and one was the early pre-B type with myeloid coexpression.
Relationship between fusion genes and ALL immunophenotypes
The immunophenotypes of ALL patients with TEL-AML1 fusion transcripts were precursor B, early 
P.C. Lin, T.T. Chang, S.R. Lin, et al
pre-B, and pre-B types. No TEL-AML1 fusion transcripts were detected in any T-or B-cell ALL patients with myeloid coexpression. The occurrence of the fusion gene was the highest in the precursor B type patients, with four (57%) of the seven patients expressing the gene. In contrast, the fusion gene was identified in only one (16.6%) of the six pre-B ALL patients.
Relationship between fusion genes and other clinical findings
Age is an important prognostic factor for ALL. Past research has shown that better prognosis is associated with ages between 1 and 10, while those aged younger than 1 or older than 10 years have poorer prognosis. The majority (15) of the study subjects was aged between 1 and 10 years; two were less than 1 year old; and eight were over 10 years old. Most (6/8) of the cases with the TEL/AML1 fusion gene were also between the ages of 1 and 10 years.
The patients were grouped according to their WBC count at the time of diagnosis: the groups were < 50 × /μL was also TEL/AML1 positive. However, none of the three patients whose WBC counts were greater than 100 × 10 3 /μL was TEL/AML1 positive.
Only one subject in this study had CNS II status (cerebrospinal fluid [CSF] cell count < 5 WBC/μL with blasts), and this particular patient was TEL/AML1 positive. All of the other subjects had CNS I status (CSF < 5 WBC/μL without blasts) and no subject had CNS III status (cell count > 5 WBC/μL with blasts) or signs of CNS leukemia at the time of diagnosis. Seventeen of the 25 subjects (68%) recruited in this study were male. TEL/AML1 was positive in seven of them, but in only one of the eight females in the study.
All of the subjects underwent a chromosome study at the time of diagnosis. Most showed a normal karyotype, but the following abnormalities were found in four subjects: hyperploidy (> 50 chromosomes); 47XY,+8; 45XY,t(5;15)(p15;q13),−17; and the Philadelphia chromosome [46XX,t(9;22)(q34;q11)]. The t(12;21)(p13;q22) abnormality was not detected in any patient.
Treatment response
The 20 newly diagnosed ALL patients underwent treatment with the protocol recommended by the TPOG. The TPOG ALL 2002 (Standard Risk) was started in 11 patients, the TPOG ALL 2002 (High Risk) in four, and the TPOG ALL 2002 (Very High Risk) in five. With one exception (a patient who tested negative for TEL-AML1), all of the patients achieved complete remission by the end of induction therapy. One TEL-AML1 positive patient relapsed during consolidation therapy and subsequently died from advanced disease. To date, all of the other 18 subjects remain in remission, with the longest follow-up period being 2 years.
Of the five relapsed cases, two were TEL-AML1 positive. Following completion of the TPOG ALL 2002 Very High Risk treatment regimen, they both achieved and remained in remission. The other three relapsed patients did not achieve remission. Two died from progressive disease and one continues to receive treatment.
Quantitative analysis of fusion genes at different disease stages
The study of bone marrow and peripheral blood samples commenced after the initiation of treatment in TEL-AML1 positive ALL patients. Of the eight TEL-AML1 positive ALL patients, samples were only available from two at the time of diagnosis, while samples collected after the start of treatment were available from the other six patients. A total of 11 bone marrow samples and nine peripheral blood samples were examined by blotting analysis, the results of which are shown in Table 4 . Only one (Case 17) of the eight cases relapsed during consolidation therapy. In the other seven cases, the proportion of lymphoblast cells fell from 95% at diagnosis to less than 2% at the completion of induction therapy, and continued to remain in remission. 0.54 9.5 mo after initial diagnosis BM = bone marrow; PB = peripheral blood; C/T = chemotherapy.
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It was observed that the expression of TEL-AML1 fusion transcripts dramatically dropped in Cases 2, 4 and 11, and a similar trend (but with a smaller amplitude) was also seen in Case 16. The bone marrow samples of Cases 2 and 4 and the peripheral blood sample of Case 11 showed a similar degree of reduced gene expression. Unfortunately, we were not able to collect both samples at various time points in the same patient. Otherwise, the analysis of peripheral blood could have been more firmly evaluated.
DISCUSSION
The TEL/AML1 fusion gene is thought to be the most common leukemia-specific fusion gene in children with ALL as it is present in 20-25% of patients. Most of these patients are aged between 1 and 10 years, have a WBC count < 50,000/μL, and have the B-lineage immunophenotype [10, 18] . Our findings are consistent with those reported in previous literature: among the TEL-AML1 fusion gene-positive patients, 88% (7/8) had WBC count < 50,000/μL, all (8/8) were of B-lineage immunophenotype, and most (75%, 6/8) were between 1 and 10 years of age.
In four of the six patients with an available series of tissue samples, the expression level of the TEL-AML1 fusion transcript matched the clinical course of the illness. The rationale behind looking for the TEL-AML1 fusion transcript as a means to detect minimal residual disease has been supported by many researchers. However, accurate quantization of the gene has more important clinical implications. For instance, de Haas and colleagues [19] and Pallisgaard and colleagues [20] provided evidence that the quantization of TEL-AML1 by real-time PCR correlated with clinical findings. Although our study did not employ real-time quantitative PCR, our results were similar to the findings of these two studies.
The limitation of this study was its small sample size. Thus, the correlation between TEL-AML1 fusion transcript expression level and disease relapse could not be reliably established from the single relapsed patient in the study. More cases will be required for future research to confirm the efficacy of our quantization method using TEL-AML1 fusion transcripts as the target gene for the estimation of disease progression. 
